PHST001 is an innovative monoclonal antibody targeting CD24, a "don't eat me" signal expressed by various cancer cells, including those found in ovarian and triple-negative breast cancer. By specifically binding to and blocking CD24, PHST001 promotes macrophage-mediated phagocytosis, facilitating the immune system's ability to recognize, engulf, and destroy cancer cells. Preclinical studies have demonstrated the potential of PHST001 to significantly reduce and even eradicate tumors in animal models, highlighting its promise as a novel cancer therapy.